Vytorin: A Combination of Ezetimibe and Simvastatin
Vytorin, a fixed-dose combination of the cholesterol absorption inhibitor ezetimibe (Zetia - Merck/Schering Plough) and the HMG-CoA reductase inhibitor ("statin") simvastatin (Zocor - Merck), has been approved by the FDA for treatment of hypercholesterolemia. It is available as tablets containing 10 mg of ezetimibe combined with 10, 20, 40 or 80 mg of simvastatin....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Vytorin: A Combination of Ezetimibe and Simvastatin
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1191
Article Code: 1191a
Date: September 13, 2004
Volume: 46
Pages: 73-74
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1191
Article Code: 1191a
Date: September 13, 2004
Volume: 46
Pages: 73-74
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)